3QB
LINCOMYCIN
Created: | 2014-10-07 |
Last modified: | 2020-06-05 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 61 |
Chiral Atom Count | 9 |
Bond Count | 62 |
Aromatic Bond Count | 0 |
Chemical Component Summary | |
---|---|
Name | LINCOMYCIN |
Synonyms | methyl (5R)-5-[(1R,2R)-2-hydroxy-1-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}propyl]-1-thio-beta-L-arabinopyranoside |
Systematic Name (OpenEye OEToolkits) | (2S,4R)-1-methyl-N-[(1R,2R)-1-[(2R,3R,4S,5R,6R)-6-methylsulfanyl-3,4,5-tris(oxidanyl)oxan-2-yl]-2-oxidanyl-propyl]-4-propyl-pyrrolidine-2-carboxamide |
Formula | C18 H34 N2 O6 S |
Molecular Weight | 406.537 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 12.01 | O=C(NC(C1OC(SC)C(O)C(O)C1O)C(O)C)C2N(C)CC(CCC)C2 |
SMILES | CACTVS | 3.385 | CCC[CH]1C[CH](N(C)C1)C(=O)N[CH]([CH](C)O)[CH]2O[CH](SC)[CH](O)[CH](O)[CH]2O |
SMILES | OpenEye OEToolkits | 1.9.2 | CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)O |
Canonical SMILES | CACTVS | 3.385 | CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O |
Canonical SMILES | OpenEye OEToolkits | 1.9.2 | CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O |
InChI | InChI | 1.03 | InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1 |
InChIKey | InChI | 1.03 | OJMMVQQUTAEWLP-KIDUDLJLSA-N |
Drug Info: DrugBank
DrugBank ID | DB01627 |
---|---|
Name | Lincomycin |
Groups |
|
Description | Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium _Streptomyces lincolnensis_ in Lincoln, Nebraska.[A190621] Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.[A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964.[L33214] |
Synonyms |
|
Brand Names |
|
Indication | Lincomycin is indicated for the treatment of serious bacterial infections by susceptible strains of streptococci, pneumococci, and staphylococci in patients who are allergic to penicillins or for situations in which a penicillin is deemed inappropriate. As with all antibacterial agents, lincomycin should only be used to treat infections proven or strongly suspected to be caused by susceptible bacteria.[L33214] |
Categories |
|
ATC-Code | J01FF02 |
CAS number | 154-21-2 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
23S ribosomal RNA | - | unknown | binder |
Alpha-1-acid glycoprotein 1 | MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDQITGKWFYIASAF... | unknown | binder |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
PubChem | 3000540 |
ChEMBL | CHEMBL1447 |
ChEBI | CHEBI:6472 |
CCDC/CSD | LINCOM01 |